The Korea Pharmaceutical and Bio-Pharma Association is set to provide training on U.S. patent risks for professionals in the domestic pharmaceutical and biotech industry.
The association announced on Thursday that it will host a Practical Training on U.S. Life Sciences Patent Responses on June 12 in the auditorium on the fourth floor of its headquarters.
This training program aims to bolster the capabilities of pharmaceutical and biotech companies pursuing global expansion through technology exports, partnerships, and overseas clinical trials, enabling them to proactively address common U.S. patent risks.
In the field, companies frequently encounter issues where negotiations collapse or transactions are delayed due to intellectual property (IP) concerns that surface during due diligence, often because they failed to conduct Freedom to Operate (FTO) analyses.
The importance of addressing U.S. patent challenges has become increasingly critical, particularly as the domestic profit landscape evolves.
The training will be structured into three sessions. Participants will delve into the realities of U.S. Life Sciences patent disputes, the fundamental concepts of FTO, practical considerations, strategies for circumventing U.S. patents (Design-Around), global dispute trends, and preparatory steps for global IP strategy and commercialization during the research and development (R&D) phase.
The association believes this program will enhance understanding of the U.S. IP environment and equip attendees with strategic skills they can immediately apply in their work.
The lectures will be led by attorney Nam In-young, a U.S. patent litigation expert licensed in New York and California. With over 10 years of experience in Life Sciences patent litigation at major law firms in both Korea and the U.S., including Latham & Watkins and Kim & Chang, Nam holds a Ph.D. in Molecular and Cell Biology from UC Berkeley.
The training targets R&D and IP personnel, business development (BD) and management planning staff, executives, and decision-makers from Life Sciences companies looking to enter or evaluate the U.S. market. The program has a capacity limit of 50 participants.
An association spokesperson emphasized that for domestic pharmaceutical and biotech companies to compete successfully in the global market, it’s crucial to proactively address U.S. patent risks. It hopes this training will help practitioners develop IP skills they can directly apply in their work.
Interested parties can register for the training through the association’s website until June 5.
